"I can't afford to increase my holdings, given the losses I have had to endure to date."
With all due respect to your personal circumstances Resourced, I don't think this is a valid reason for not pursuing a capital raising or for deferring upcoming US trials for Vitrogro.
Regardless of the recent setback for CE mark, provided that any proposed CR is equitable to existing retail investors then I don't have a problem with management raising more money for US trails and working capital so long as it is used wisely and spent efficiently.
TIS Price at posting:
27.0¢ Sentiment: LT Buy Disclosure: Held
